STOCK TITAN

Spin-off dividend tax info posted by AnaptysBio (NASDAQ: ANAB)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

AnaptysBio, Inc. is providing tax information to its stockholders about the dividend they received from the separation and spin-off of First Tracks Biotherapeutics, Inc. The company has filed IRS Form 8937 and is making the same information available in the Investors section of its website.

The Form 8937 explains how the spin-off dividend is treated for tax purposes and how stockholders should determine their adjusted tax basis. AnaptysBio emphasizes that this material is for informational purposes only and urges stockholders to consult their own tax advisors about their specific situations.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
8-K signature date May 29, 2026 Date the report was signed by the Chief Financial Officer
Form 8937 regulatory
"The Form 8937 provides information about the dividend received by stockholders"
Form 8937 is a U.S. Internal Revenue Service disclosure companies file to explain how a corporate action—like a merger, spin-off, or stock split—changes the tax cost (tax basis) of an investor’s shares. It matters because that tax cost determines how much profit or loss you report when you sell, so the form is like an instruction sheet showing how to split or adjust the original purchase price for tax reporting.
spin-off financial
"resulting from the separation and spin-off of First Tracks Biotherapeutics, Inc."
A spin-off happens when a company creates a new, independent business by separating part of itself, like splitting off a division into its own company. This often happens so the new company can focus better on its own goals or attract different investors. It matters because it can lead to more growth opportunities and clearer focus for both companies.
dividend financial
"information about the dividend received by stockholders resulting from the separation"
A dividend is a payment that a company gives to its shareholders, usually from its profits. It’s like a bonus or reward for owning the company's stock, and it can provide a steady income stream for investors. Companies pay dividends to share their success with the people who own their stock.
tax basis financial
"how the dividend is treated by the Company’s stockholders and how the change in tax basis is determined"
Tax basis is the original value assigned to an asset for tax purposes, adjusted over time for things like improvements, depreciation, or distributions; it serves as the starting point used to calculate gain or loss when the asset is sold. For investors, it determines how much of a sale is treated as taxable profit—think of it as the purchase price on a receipt you subtract from the selling price to see what portion is taxed, so a higher basis usually means a smaller tax bill.
Regulation FD Disclosure regulatory
"Item 7.01 Regulation FD Disclosure."
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
0001370053false00013700532026-05-292026-05-29

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 29, 2026

 

 

ANAPTYSBIO, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37985

20-3828755

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10770 Wateridge Circle, Suite 210

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 858 362-6295

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.001 per share

 

ANAB

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 7.01 Regulation FD Disclosure.

AnaptysBio, Inc. (the “Company”) has filed Form 8937 with the IRS and will also post Form 8937 information under the “Investors” section of its website at www.anaptysbio.com. The Form 8937 provides information about the dividend received by stockholders resulting from the separation and spin-off of First Tracks Biotherapeutics, Inc. (“First Tracks”) from the Company. The Form 8937 also provides guidance on how the dividend is treated by the Company’s stockholders and how the change in tax basis is determined.

The Company’s stockholders are urged to consult their own tax advisor as to the particular tax consequences of the distribution of the First Tracks common stock, including potential tax consequences under state, local and non-U.S. tax laws. The Company is providing the details on the Form 8937 for informational purposes only and is not to be considered or construed as legal or tax advice.

The information furnished in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

ANAPTYSBIO, INC.

 

 

 

 

Date:

May 29, 2026

By:

/s/ Christopher M. Murphy

 

 

 

Christopher M. Murphy
Chief Financial Officer

 


FAQ

What did AnaptysBio (ANAB) announce in this 8-K filing?

AnaptysBio announced that it has filed IRS Form 8937 and will post related information on its website. The form explains tax treatment of the dividend from the First Tracks Biotherapeutics spin-off for AnaptysBio stockholders.

What is the purpose of AnaptysBio’s IRS Form 8937 regarding First Tracks Biotherapeutics?

The Form 8937 provides details on the dividend received from the First Tracks Biotherapeutics spin-off. It explains how the dividend is treated for tax purposes and how stockholders should determine changes to their tax basis in the related shares.

Where can AnaptysBio (ANAB) investors find the Form 8937 tax information?

Investors can access the Form 8937 information in the Investors section of AnaptysBio’s website. The company has also filed the form with the IRS, making the same explanatory tax details available to stockholders online for reference.

Does AnaptysBio’s Form 8937 replace personalized tax advice for ANAB stockholders?

No. AnaptysBio states the Form 8937 information is for informational purposes only. The company urges stockholders to consult their own tax advisors about the First Tracks dividend, including potential state, local, and non-U.S. tax consequences.

How is the First Tracks Biotherapeutics spin-off described for AnaptysBio shareholders?

The transaction is described as a separation and spin-off that resulted in a dividend of First Tracks common stock. Form 8937 explains how this dividend is treated for AnaptysBio stockholders and how it affects their tax basis in the distributed shares.

Filing Exhibits & Attachments

1 document